ALLEGAN — The Perrigo Company (Nasdaq: PRGO) announced that it has begun shipments of over-the-counter nicotine polacrilex mini lozenge USP, 2 mg (mint flavor) and 4 mg (mint flavor).
This launch represents the first to market nicotine mini lozenge products for the store brand market. The mint flavored mini lozenges are marketed under retailer and wholesalers’ store, or own brand labels and are comparable to GlaxoSmithKline’s Nicorette Mini Lozenge. The product is indicated to reduce withdrawal symptoms, including nicotine craving, associated with quitting smoking.
“This launch strengthens Perrigo’s leading store brand position in smoking cessation products, which also includes coated and uncoated flavored gums and regular size lozenges,” said Joseph C. Papa, Perrigo’s chairman, president and CEO. Nicorette Mini Lozenge is selling at an annual rate estimated at over $30 million at all retail outlets.
From its beginnings as a packager of generic home remedies in 1887, Perrigo has grown to become a leading global developer, manufacturer and distributor of over-the-counter and generic prescription pharmaceuticals, nutritional products and active pharmaceutical ingredients and is the world’s largest manufacturer of OTC pharmaceutical products for the store brand market. Perrigo operates mainly in the United States, the United Kingdom, Mexico, Israel and Australia, with smaller operations in Canada, China and Latin America.
More at www.perrigo.com.